Azithromycin in the Treatment of Legionella Pneumonia Requiring Hospitalization

Clinical Infectious Diseases

Volumn 37, Issue 11, 2003, Pages 1475-1480

  Plouffe, Joseph F ^a,h   Breiman, Robert F ^c   Fields, Barry S ^c   Herbert, Mark ^b   Inverso, Jill ^d   Knirsch, Charles ^d   Kolokathis, Antonia ^d   Marrie, Thomas J ^f   Nicolle, Lindsay ^g   Schwartz, Douglas B ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b MOUNT CARMEL HEALTH SYSTEM   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d PFIZER INC   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ADULT; AGED; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HEPATITIS; HOSPITALIZATION; HUMAN; INJECTION PAIN; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; MALE; MULTICENTER STUDY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SEROTYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; LEGIONELLA; LEGIONNAIRES' DISEASE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0345119082     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379329     Document Type: Article

References (42)

1. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization. Rev Infect Dis 1989; 11:586-99.
2. Marston BJ, Lipman, HB, Breiman RF. Surveillance for Legionnaires' disease: risk factors for morbidity and mortality. Arch Intern Med 1994; 154:2417-22.
3. Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337:682-7.
4. Ruf B, Schurmann D, Horbach I, Fehrenbach FJ, Pohle HD. Prevalence and diagnosis of Legionella pneumonia: a 3-year prospective study with emphasis on application of urinary antigen detection. J Infect Dis 1990; 162:1341-8.
5. Lieberman D, Porath A, Schlaeffer F, Lieberman D, Boldur I. Legionella species community-acquired pneumonia: a review of 56 hospitalized adult patients. Chest 1996; 109:1243-9.
6. Kuzman I, Soldo I, Schonwald, S, Culig J. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis 1995; 27:503-5.
7. Macfarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. Lancet 1982; 2:255-8.
8. Walder, M, Svanteson B, Ursing J, Cronberg S, Johnsson T, Forsgren A. Incidence of Legionella pneumophila in acute lower respiratory tract infections. Scand J Infect Dis 1981; 13:159-60.
9. Friis-Møller A, Rechnitzer C, Black FT, Collins MT, Lind K, Aalund O. Prevalence of Legionnaires' disease in pneumonia patients admitted to Danish department of infectious diseases. Scand J Infect Dis 1986; 18:321-8.
10. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69:307-16.
11. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157:1709-18.
12. Plouffe JF, File TM Jr, Breiman RF, et al. Reevaluation of the definition of Legionnaires' disease: use of the urinary assay. Community Based Pneumonia Incidence Study Group. Clin Infect Dis 1995; 20:1286-91.
13. Ruf B, Schurmann D, Horbach I, Fehrenbach FJ, Pohle HD. The incidence of Legionella pneumonia: a 1-year prospective study in a large community hospital. Lung 1989; 167:11-22.
14. Heath CH, Grove DI, Looke, DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996; 15:286-90.
15. File TM Jr, Tan JS, Plouffe JF. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 1998; 12:569-92.
16. File T Jr, Plouffe JF Jr, Breiman RF, Skelton SK. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin Infect Dis 1999; 29:426-8.
17. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
18. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-82.
19. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000; 160:1399-407.
20. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72.
21. Edelstein PH, Edelstein MAC. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother 1991; 35:180-1.
22. Fitzgeorge RB, Lever S, Baskerville A. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J Antimicrob Chemother 1993; 31(Suppl E):171-6.
23. Fitzgeorge RB, Featherstone, AS, Baskerville, A. The effect of ofloxacin on the intracellular growth of Legionella pneumophila in guinea pig alveolar phagocytes. J Antimicrob Chemother 1988; 22(Suppl C):53-7.
24. File T Jr, Segreti J, Dunbar L, Player R, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965-72.
25. Schönwald S, Kuzman I, Oreskovic K, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study. Infection 1999; 27:198-202.
26. Myburgh J, Nagel GJ, Petschel E. The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1993; 31(Suppl E):163-9.
27. Sanchez F, Mensa J, Martinez JA, et al. Treatment of pneumonia caused by Legionella with azithromycin. Rev Esp Quimioter 1998; 11:147-51.
28. Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med 1999; 130:864.
29. Yu V, Vergis EN. New macrolides or new quinolones as monotherapy for patients with community-acquired pneumonia: our cup runneth over? Chest 1998; 113:1158-9.
30. Vergis EN, Indorf A, File TM Jr, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160:1294-300.
31. Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000; 44:1796-802.
32. Reda C, Quaresima T, Pastoris MC. In vitro activity of six intracellular antibiotics against Legionella pneumophila strains of human and environmental origin. J Antimicrob Chemother 1994; 33:757-64.
33. Swanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY, Yu VL. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92: 61-8.
34. Ball P. The future role and importance of macrolides. J Hosp Infect 1991; 19(Suppl A):47-59.
35. Morris DL, De Souza A, Jones JA, Morgan WE. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur J Clin Microbiol Infect Dis 1991; 10:859-61.
36. Andrews JM, Ashby JP, Honeybourne D. Persistence of high concentrations of azithromycin in the lung following a single oral dose. Am Rev Resp Dis 1990; 141:A598.
37. Stamler DA, Edelstein MAC, Edelstein PH. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila - infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother 1994; 38:217-22.
38. Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990; 25(Suppl):123-6.
39. Tan JS, File TM Jr, DiPersio JR, Hamor R, Saravolatz LD, Stout JE. Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila. Clin Infect Dis 2001; 32:1562-6.
40. Kashuba AD, Ballow CH. Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Diagn Microbiol Infect Dis 1996; 24:129-39.
41. Ramirez JA, Summersgill JT. Rapid tests for the diagnosis of Legionella infections. J Ky Med Assoc 1994; 92:62-5.
42. Roig J, Rello J. Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother 2003; 51:1119-29.